Ofloxacin 0.3%, 5mL Ophthalmic Solution

NDC: 70756-607-30

Ofloxacin 0.3% Ophthalmic Solution, 5 mL — Lifestar Pharma

Active ingredients	Ofloxacin 0.3% (3 mg/mL)
Dosage form	Sterile ophthalmic solution
Route	Topical ophthalmic
Size	5 mL
Manufacturer	Lifestar Pharma
NDC	70756-607-30

Indications and Usage

Treatment of bacterial conjunctivitis and bacterial corneal ulcers caused by susceptible strains of organisms including Staphylococcus aureus, Streptococcus pneumoniae, Pseudomonas aeruginosa, and Haemophilus influenzae.

Dosage and Administration

For conjunctivitis, instill one to two drops every two to four hours on Days 1 and 2, then four times daily on Days 3 through 7. For corneal ulcer, instill one to two drops every 30 minutes while awake initially, with a tapering schedule thereafter.

Warnings and Precautions

• Not for injection; do not inject subconjunctivally or introduce into the anterior chamber
• Rare serious hypersensitivity and anaphylactic reactions, and severe skin reactions such as Stevens-Johnson syndrome, have been reported
• Prolonged use may result in overgrowth of non-susceptible organisms, including fungi
• Avoid contact lens wear during active bacterial infection

Contraindications

Contraindicated in patients with hypersensitivity to ofloxacin, to other quinolones, or to any component of the formulation.

Adverse Reactions

The most common adverse reactions are transient ocular burning or discomfort, stinging, redness, itching, and blurred vision.

Storage and Handling

Store at 20°C to 25°C (68°F to 77°F).

How Supplied

Sterile ophthalmic solution supplied in a plastic dropper bottle, including a 5 mL fill.

Professional use only. Clinical information summarized from FDA-approved prescribing information (Structured Product Labeling); refer to the full prescribing information via DailyMed for complete details.

If you have any questions related to DSCSA compliance, transaction history, regulatory data or quality assurance, please contact our team at compliance@dryeyerescue.com for more information.